RxDoctor Payments Data

Edward Morales, MD

Infectious Disease · Green Bay, WINPI 1770579757

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $61,855 of the $81,650 with a category attached, or 75.8%. Gilead accounts for 99.8% of it on its own, with 3 other manufacturers making up the rest. Among infectious disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,650in general payments, 2019–2025

Across 177 payments — averaging $461.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$82K
  • Insmed, Inc.$90
  • Viiv Healthcare Company$18
  • Nestle Healthcare Nutrition Inc.$16

What the payments were for

  • Speaking & faculty fees$61,85576%
  • Travel & lodging$15,66219%
  • Food & beverage$4,1175%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,650 in reported general payments places this provider in the 95th percentile of 133 infectious disease providers in Wisconsin.

See all infectious disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$57,683
Medicare patients
190
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala86$353,887
DescovyEmtricitabine/Tenofov Alafenam20$43,283
Daptomycin55$34,798
TivicayDolutegravir Sodium13$29,503
Meropenem68$14,375
ErtapenemErtapenem Sodium40$12,528
CeftriaxoneCeftriaxone Sodium56$8,551
Voriconazole22$8,197
Cefpodoxime Proxetil12$4,440
Cephalexin156$3,843
Cefdinir34$2,402
Itraconazole11$2,223
Fluconazole15$1,337
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim60$1,302
Doxycycline Hyclate51$1,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$81,526$397,170106 claims
Viiv Healthcare CompanyTivicay$18$29,50313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 infectious disease providers in Wisconsin.

Other infectious disease in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →